Live Breaking News & Updates on Sglt2 Inhibitors

Stay updated with breaking news from Sglt2 inhibitors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Data Make It Clear: SGLT2 Inhibitors Can Be Used in Most Common Kidney Diagnoses, Says Dr William G. Herrington

Data shows sodium-glucose cotransporter-2 (SGLT2) inhibitors are efficacious and can be used in almost all common kidney diagnoses, explained William G. Herrington, MD, MA, MBBS, Nuffield Department of Population Health, University of Oxford. ....

Williamg Herrington , Nuffield Department Of Population Health , University Of Oxford , Nuffield Department , Population Health , Oxford Kidney , Kidney Week , Kidney Disease , Sglt2 Inhibitors ,

Semaglutide Prescribing Surged in the Past Year

Prescriptions for Wegovy rose sixfold between December 2022 and June 2023 while those for Ozempic jumped 65%, with general and family practice providers writing the majority of prescriptions. ....

United States , Wayne State University School Of Medicine , Sharonw Lahiri , S Sethuk Reddy , Colin Banas , American Association Of Clinical Endocrinologists , Medscape Medical , American Association , Clinical Endocrinologists , Patients Actually Getting , Wayne State University School , Henry Ford Hospital , Diabetes Mellitus Type 2 , Iabetes Mellitus Type Ii , Type 2 Diabetes , Weight Loss , Weight Management , Primary Care , Practice Management , Prescription Drug , Sglt2 Inhibitors , Odium Glucose Transporter 2 Inhibitors , Odium Glucose Co Transporter 2 Inhibitors , Sodium Glucose Cotransporter 2 Inhibitors ,

SGLT2 Inhibitors in T2DM Linked to Lower GI Cancer Risk

Researchers used a large national database to compare risk of all types of GI cancers associated with popular drug classes used to treat type 2 diabetes. ....

British Columbia , United States , Shu Yen Emily Chan , Kennethj Vega , Augusta University , American College Of Gastroenterology , Division Of Gastroenterology , College Of Georgia , Weiss Memorial Hospital , American College , Medical College , Colorectal Cancer , Diabetes Mellitus Type 2 , Iabetes Mellitus Type Ii , Type 2 Diabetes , Alignant Neoplasia , Colon Cancer , Alignant Colon Neoplasm , Malignant Pancreatic Neoplasm , Pancreatic Cancer , Ancer Pancreatic , Cancer Risk , Gastric Cancer , Alignant Stomach Neoplasm , Noncolorectal Gastrointestinal Cancer , Oncolorectal Gi Cancer ,

Will Kidney Disease Patients Finally Receive New Drug Class?

Dapagliflozin became the first SGLT2 inhibitor approved for CKD alone just over 2 years ago, but uptake has lagged. Could a similar label gain for empagliflozin, plus a new recommendation, spark change? ....

San Francisco , United States , Donalda Molony , Tazeenh Jafar , Diana Kwong , Drug Administration , Kidney Research Institute , University Of California , University Of Washington , Kidney Disease , Improving Global Outcomes , Gross Underuse , Medical School , Ian De Boer , Chi Yuan Hsu , Choosing Among Dapa , Chronic Renal Failure , Hronic Kidney Failure , Hronic Kidney Disease Ckd , Chronic Kidney Disease , Sglt2 Inhibitors , Odium Glucose Transporter 2 Inhibitors , Odium Glucose Co Transporter 2 Inhibitors , Sodium Glucose Cotransporter 2 Inhibitors , Renal Failure , Enal Insufficiency ,

Higher Fracture Risk Not Seen With SGLT2 Inhibitors

Increased fracture risk seen in short-term studies may have been due to hypovolemia or osmotic diuresis, resulting in falls, rather than an effect on bone. ....

United States , British Columbia , Veerle Van Hulten , Van Hulten , Sarah Berry , Drug Administration , Maastricht University , Society For Bone , Marcus Institute For Aging Research , Mineral Research , Harvard Medical School , Marcus Institute , Aging Research , Sglt2 Inhibitors , Odium Glucose Transporter 2 Inhibitors , Odium Glucose Co Transporter 2 Inhibitors , Sodium Glucose Cotransporter 2 Inhibitors , Diabetes Mellitus Type 2 , Iabetes Mellitus Type Ii , Type 2 Diabetes , Elderly Concerns Of Older Adults , Geriatrics Elder Care , Dpp 4 Inhibitors , Dipeptidyl Peptidase 4 Inhibitors ,